Natsuki Ishida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natsuki Ishida has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Ken Sugimoto
First Department of Medicine Hamamatsu University School of Medicine Shizuoka Japan
12 shared publications- Ken Sugimoto
First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan
11 shared publications Kenichi Takahashi
First Department of Medicine Hamamatsu University School of Medicine Shizuoka Japan
11 shared publications- Mihoko Yamade
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
11 shared publications Moriya Iwaizumi
Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
11 shared publicationsSatoshi Osawa
Department of Endoscopic and Photodynamic Medicine Hamamatsu University School of Medicine Shizuoka Japan
11 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Ectopic gastric squamous metaplasia with concomitant well-differentiated adenocarcinoma: a case report
Gastric squamous metaplasia is a rare condition whose clinical significance and malignant potential remain unclear. Most reported cases are located in the
- 18 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessEctopic gastric squamous metaplasia with concomitant well-differentiated adenocarcinoma: a case report
Gastric squamous metaplasia is a rare condition whose clinical significance and malignant potential remain unclear. Most reported cases are located in the
- Open Access
- 10 July 2026
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 32, e953332
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects - Article abstract #953332
- 10 July 2026
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 32, e953332
Open AccessEffect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects - Article abstract #953332
- Open Access
Comparison of Changes in Biomarkers With Changes in Endoscopic Scores in Patients With Ulcerative Colitis: A Single‐Center, Retrospective, Observational Study
Aim: Fecal occult blood concentration, fecal calprotectin (FC) level, serum C‐reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR) are valuable biomarkers for ulcerative colitis (UC). However, their clinical utility for longitudinal disease assessment remains unclear. This retrospective, observational study assessed correlations between biomarker changes and endoscopic activity scores in UC. Methods: Spearman's rank correlation coefficient analysis was applied to examine the relationship between longitudinal variations in endoscopic activity scores, including the Mayo endoscopic subscore (MES), ulcerative colitis endoscopic index of severity (UCEIS), and sum of Mayo endoscopic subscores (S‐MES), and corresponding biomarker changes in patients with UC. Results: The study included 97 patients, contributing to 145 observation intervals (48 contributed two intervals each and 49 contributed one each). All endoscopic scores and biomarkers were significantly correlated with disease activity, with corresponding increases or decreases ( p < 0.05). Changes in MES and S‐MES correlated most strongly with FC level changes ( r = 0.62 and 0.66, respectively). Changes in the UCEIS exhibited the strongest correlation with fecal occult blood concentration changes ( r = 0.67). Changes in fecal occult blood and FC ( r = 0.55) and in serum CRP and ESR ( r = 0.58) were strongly correlated. Conclusions: All four biomarkers reflected endoscopic activity in UC. Changes in fecal occult blood concentration and FC level had stronger correlations with endoscopic score changes than blood biomarker concentration changes. FC assessment is valuable for monitoring inflammatory activity during remission maintenance, whereas fecal occult blood concentration reflects mucosal bleeding. Serum CRP level and ESR are useful adjunctive biomarkers, particularly in cases of increased disease activity.
Open AccessComparison of Changes in Biomarkers With Changes in Endoscopic Scores in Patients With Ulcerative Colitis: A Single‐Center, Retrospective, Observational Study
Aim: Fecal occult blood concentration, fecal calprotectin (FC) level, serum C‐reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR) are valuable biomarkers for ulcerative colitis (UC). However, their clinical utility for longitudinal disease assessment remains unclear. This retrospective, observational study assessed correlations between biomarker changes and endoscopic activity scores in UC. Methods: Spearman's rank correlation coefficient analysis was applied to examine the relationship between longitudinal variations in endoscopic activity scores, including the Mayo endoscopic subscore (MES), ulcerative colitis endoscopic index of severity (UCEIS), and sum of Mayo endoscopic subscores (S‐MES), and corresponding biomarker changes in patients with UC. Results: The study included 97 patients, contributing to 145 observation intervals (48 contributed two intervals each and 49 contributed one each). All endoscopic scores and biomarkers were significantly correlated with disease activity, with corresponding increases or decreases ( p < 0.05). Changes in MES and S‐MES correlated most strongly with FC level changes ( r = 0.62 and 0.66, respectively). Changes in the UCEIS exhibited the strongest correlation with fecal occult blood concentration changes ( r = 0.67). Changes in fecal occult blood and FC ( r = 0.55) and in serum CRP and ESR ( r = 0.58) were strongly correlated. Conclusions: All four biomarkers reflected endoscopic activity in UC. Changes in fecal occult blood concentration and FC level had stronger correlations with endoscopic score changes than blood biomarker concentration changes. FC assessment is valuable for monitoring inflammatory activity during remission maintenance, whereas fecal occult blood concentration reflects mucosal bleeding. Serum CRP level and ESR are useful adjunctive biomarkers, particularly in cases of increased disease activity.
- Open Access
- 29 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2609
Real-World Evaluation of an AI-Assisted Diagnostic Support System for Early Gastric Cancer: Diagnostic Performance, Confidence Stratification, and Determinants of False-Positive Diagnosis
Background/Objectives: Artificial intelligence (AI)-assisted endoscopy has shown high sensitivity for early gastric cancer detection; however, false-positive diagnoses remain a clinical challenge. This study aimed to evaluate the real-world diagnostic performance of a commercially available AI system and to identify factors associated with false-positive diagnoses, focusing on repeated AI evaluations and confidence stratification. Methods: This single-center retrospective study included 47 patients with 89 localized gastric lesions evaluated between March 2024 and March 2025. Endoscopic examinations were performed under white-light, non-magnified observation with repeated AI assessments of each lesion. The rates of “Consider biopsy” (B) judgments were calculated. Lesions with a B judgment rate of ≥50% were defined as AI-positive and classified into four AI confidence categories. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Factors associated with false-positive diagnoses were analyzed using penalized logistic regression. Results: The AI system demonstrated a sensitivity of 97.6% and an NPV of 95.7%, with a specificity of 45.8%. Pathology-positive rates decreased stepwise across the four AI confidence categories (p < 0.001). Among AI-positive lesions, low regional reproducibility, lesion size ≥ 30 mm, scar, and erosion were independently associated with false-positive diagnoses. In analyses restricted to non-neoplastic lesions, lesion size ≥ 30 mm remained significantly associated with false-positive diagnosis. Conclusions: In real-world clinical practice, a commercially available AI system provides high sensitivity for early gastric cancer detection. Incorporating confidence stratification and regional reproducibility into clinical decision-making may enhance the effective use of AI-assisted endoscopic diagnosis beyond binary interpretations.
- 29 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2609
Open AccessReal-World Evaluation of an AI-Assisted Diagnostic Support System for Early Gastric Cancer: Diagnostic Performance, Confidence Stratification, and Determinants of False-Positive Diagnosis
Background/Objectives: Artificial intelligence (AI)-assisted endoscopy has shown high sensitivity for early gastric cancer detection; however, false-positive diagnoses remain a clinical challenge. This study aimed to evaluate the real-world diagnostic performance of a commercially available AI system and to identify factors associated with false-positive diagnoses, focusing on repeated AI evaluations and confidence stratification. Methods: This single-center retrospective study included 47 patients with 89 localized gastric lesions evaluated between March 2024 and March 2025. Endoscopic examinations were performed under white-light, non-magnified observation with repeated AI assessments of each lesion. The rates of “Consider biopsy” (B) judgments were calculated. Lesions with a B judgment rate of ≥50% were defined as AI-positive and classified into four AI confidence categories. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Factors associated with false-positive diagnoses were analyzed using penalized logistic regression. Results: The AI system demonstrated a sensitivity of 97.6% and an NPV of 95.7%, with a specificity of 45.8%. Pathology-positive rates decreased stepwise across the four AI confidence categories (p < 0.001). Among AI-positive lesions, low regional reproducibility, lesion size ≥ 30 mm, scar, and erosion were independently associated with false-positive diagnoses. In analyses restricted to non-neoplastic lesions, lesion size ≥ 30 mm remained significantly associated with false-positive diagnosis. Conclusions: In real-world clinical practice, a commercially available AI system provides high sensitivity for early gastric cancer detection. Incorporating confidence stratification and regional reproducibility into clinical decision-making may enhance the effective use of AI-assisted endoscopic diagnosis beyond binary interpretations.
- Open Access
- 5 January 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1) , 67
Nonspecific mediastinal lymphadenopathy is associated with metachronous multiple cancers following endoscopic submucosal dissection of esophageal squamous cell carcinoma
Background Endoscopic submucosal dissection is the standard treatment for superficial esophageal squamous cell carcinoma. However, esophageal preservation following this procedure increases the risk of metachronous multiple cancers. Lugol-voiding lesion grade and alcohol-related genetic polymorphisms have been identified as risk factors, but the role of nonspecific mediastinal lymphadenopathy remains unclear. Methods We retrospectively analyzed the data of 154 patients who underwent curative endoscopic submucosal dissection for esophageal squamous cell carcinoma at Hamamatsu University Hospital between 2015 and 2024. Pretreatment computed tomography was used to evaluate the Lugol-voiding lesion grade and nonspecific mediastinal lymphadenopathy. Associations with pathological findings and the development of metachronous multiple esophageal squamous cell carcinoma were assessed using Kaplan–Meier and Cox regression analyses. Results Nonspecific mediastinal lymphadenopathy was identified in 68 patients (59.6%). Pathological analysis including 154 patients revealed that nonspecific mediastinal lymphadenopathy was significantly associated with lymphovascular invasion (P = 0.026) but not with invasion depth or curative resection. During follow-up and metachronous analysis including 114 patients, 21 patients developed metachronous multiple esophageal squamous cell carcinoma. Both Lugol-voiding lesion grade and nonspecific mediastinal lymphadenopathy were independent predictors of recurrence. Subgroup analysis restricted to Lugol-voiding lesion grade B/C cases confirmed that nonspecific mediastinal lymphadenopathy remained predictive of recurrence-free survival (P = 0.007). Conclusions Nonspecific mediastinal lymphadenopathy independently predicts the development of metachronous esophageal squamous cell carcinoma after endoscopic submucosal dissection. Evaluation of nonspecific mediastinal lymphadenopathy in combination with Lugol-voiding lesion grade may improve risk stratification and optimize surveillance strategies.
- 5 January 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1) , 67
Open AccessNonspecific mediastinal lymphadenopathy is associated with metachronous multiple cancers following endoscopic submucosal dissection of esophageal squamous cell carcinoma
Background Endoscopic submucosal dissection is the standard treatment for superficial esophageal squamous cell carcinoma. However, esophageal preservation following this procedure increases the risk of metachronous multiple cancers. Lugol-voiding lesion grade and alcohol-related genetic polymorphisms have been identified as risk factors, but the role of nonspecific mediastinal lymphadenopathy remains unclear. Methods We retrospectively analyzed the data of 154 patients who underwent curative endoscopic submucosal dissection for esophageal squamous cell carcinoma at Hamamatsu University Hospital between 2015 and 2024. Pretreatment computed tomography was used to evaluate the Lugol-voiding lesion grade and nonspecific mediastinal lymphadenopathy. Associations with pathological findings and the development of metachronous multiple esophageal squamous cell carcinoma were assessed using Kaplan–Meier and Cox regression analyses. Results Nonspecific mediastinal lymphadenopathy was identified in 68 patients (59.6%). Pathological analysis including 154 patients revealed that nonspecific mediastinal lymphadenopathy was significantly associated with lymphovascular invasion (P = 0.026) but not with invasion depth or curative resection. During follow-up and metachronous analysis including 114 patients, 21 patients developed metachronous multiple esophageal squamous cell carcinoma. Both Lugol-voiding lesion grade and nonspecific mediastinal lymphadenopathy were independent predictors of recurrence. Subgroup analysis restricted to Lugol-voiding lesion grade B/C cases confirmed that nonspecific mediastinal lymphadenopathy remained predictive of recurrence-free survival (P = 0.007). Conclusions Nonspecific mediastinal lymphadenopathy independently predicts the development of metachronous esophageal squamous cell carcinoma after endoscopic submucosal dissection. Evaluation of nonspecific mediastinal lymphadenopathy in combination with Lugol-voiding lesion grade may improve risk stratification and optimize surveillance strategies.
- 11 August 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Role of Sepsis Markers as Potential Biomarkers for Inflammatory Bowel Disease
Goals: This study aimed to investigate whether sepsis markers act as biomarkers of ulcerative colitis (UC) and Crohn’s disease (CD). Background: The identification of noninvasive biomarkers for inflammatory bowel disease (IBD) is advantageous. This prospective observational study investigated whether the sepsis markers, interleukin-6 (IL-6), presepsin (PSEP), procalcitonin (PCT), and pentraxin 3 (PTX3), act as biomarkers of UC and CD. Study: Patients with UC or CD underwent endoscopy and assessment of the abovementioned sepsis markers, C-reactive protein (CRP), and leucine-rich alpha 2 glycoprotein (LRG). We prospectively examined the association of these markers with clinical activity and endoscopic scores, including the Mayo endoscopic subscore (MES) and simple endoscopic score for Crohn’s disease (SES-CD). Results: Eighty-eight patients with UC and 49 patients with CD were enrolled. MES significantly correlated with LRG, CRP, IL-6, PSEP, and PTX3 in patients with UC. SES-CD significantly correlated with LRG, CRP, IL-6, and PTX3 in patients with CD. In UC, MES to 3 groups showed significantly higher LRG, CRP, and IL-6 levels than the MES 0 to 1 groups. The LRG, CRP, IL-6, PSEP, and PTX3 levels were significantly higher in the SES-CD ≥3 group than in the SES-CD ≤2 group. Conclusions: IL-6 in UC and IL-6, PSEP, and PTX3 in CD are potential biomarkers. Overall, our findings could promote better management of IBD.
- 11 August 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Role of Sepsis Markers as Potential Biomarkers for Inflammatory Bowel Disease
Goals: This study aimed to investigate whether sepsis markers act as biomarkers of ulcerative colitis (UC) and Crohn’s disease (CD). Background: The identification of noninvasive biomarkers for inflammatory bowel disease (IBD) is advantageous. This prospective observational study investigated whether the sepsis markers, interleukin-6 (IL-6), presepsin (PSEP), procalcitonin (PCT), and pentraxin 3 (PTX3), act as biomarkers of UC and CD. Study: Patients with UC or CD underwent endoscopy and assessment of the abovementioned sepsis markers, C-reactive protein (CRP), and leucine-rich alpha 2 glycoprotein (LRG). We prospectively examined the association of these markers with clinical activity and endoscopic scores, including the Mayo endoscopic subscore (MES) and simple endoscopic score for Crohn’s disease (SES-CD). Results: Eighty-eight patients with UC and 49 patients with CD were enrolled. MES significantly correlated with LRG, CRP, IL-6, PSEP, and PTX3 in patients with UC. SES-CD significantly correlated with LRG, CRP, IL-6, and PTX3 in patients with CD. In UC, MES to 3 groups showed significantly higher LRG, CRP, and IL-6 levels than the MES 0 to 1 groups. The LRG, CRP, IL-6, PSEP, and PTX3 levels were significantly higher in the SES-CD ≥3 group than in the SES-CD ≤2 group. Conclusions: IL-6 in UC and IL-6, PSEP, and PTX3 in CD are potential biomarkers. Overall, our findings could promote better management of IBD.
- Open Access
Lymphocyte Fractions as Indicators of T‐Helper 1/T‐Helper 2 Cytokine Profiles in Inflammatory Bowel Disease
Aims: Inflammatory bowel disease is characterized by various cytokine patterns. In this study, we aimed to investigate the markers that can distinguish Th1/Th2 cytokines in patients with inflammatory bowel disease.Methods and Results: In patients with inflammatory bowel disease treated at our hospital, the Th1/Th2 ratio (interferon‐γ/interleukin‐4 ratio), serum immunoglobulin E level, leucine‐rich alpha 2 glycoprotein level, serum amyloid A level, and leukocyte fraction were measured simultaneously, and the relationship between them was examined. We enrolled 108 patients with Crohn's disease and 153 patients with ulcerative colitis. No significant difference was observed in the Th1/Th2 ratio between the ulcerative colitis and Crohn's disease groups. In the inflammatory bowel disease and Crohn's disease groups, the lymphocyte fraction was significantly correlated with the Th1/Th2 ratio (r = 0.154, p = 0.013 and r = 0.204, p = 0.0346, respectively). In ulcerative colitis, lymphocyte fraction and Th1/Th2 ratio were significantly correlated in the group without steroid treatment; however, no significant correlation was observed in the steroid‐treated group. Serum immunoglobulin E, leucine‐rich alpha 2 glycoproteins, and serum amyloid A levels did not significantly correlate with the Th1/Th2 ratio.Conclusions: The lymphocyte fraction may serve as a marker of Th1/Th2 cytokines and could be particularly useful in non‐steroid‐treated patients.
Open AccessLymphocyte Fractions as Indicators of T‐Helper 1/T‐Helper 2 Cytokine Profiles in Inflammatory Bowel Disease
Aims: Inflammatory bowel disease is characterized by various cytokine patterns. In this study, we aimed to investigate the markers that can distinguish Th1/Th2 cytokines in patients with inflammatory bowel disease.Methods and Results: In patients with inflammatory bowel disease treated at our hospital, the Th1/Th2 ratio (interferon‐γ/interleukin‐4 ratio), serum immunoglobulin E level, leucine‐rich alpha 2 glycoprotein level, serum amyloid A level, and leukocyte fraction were measured simultaneously, and the relationship between them was examined. We enrolled 108 patients with Crohn's disease and 153 patients with ulcerative colitis. No significant difference was observed in the Th1/Th2 ratio between the ulcerative colitis and Crohn's disease groups. In the inflammatory bowel disease and Crohn's disease groups, the lymphocyte fraction was significantly correlated with the Th1/Th2 ratio (r = 0.154, p = 0.013 and r = 0.204, p = 0.0346, respectively). In ulcerative colitis, lymphocyte fraction and Th1/Th2 ratio were significantly correlated in the group without steroid treatment; however, no significant correlation was observed in the steroid‐treated group. Serum immunoglobulin E, leucine‐rich alpha 2 glycoproteins, and serum amyloid A levels did not significantly correlate with the Th1/Th2 ratio.Conclusions: The lymphocyte fraction may serve as a marker of Th1/Th2 cytokines and could be particularly useful in non‐steroid‐treated patients.
- Open Access
- 17 June 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (9) , 2944-2946
Annual Infliximab Monitoring After Treatment Optimization
Infliximab (IFX), a TNF-α inhibitor, remains a key treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, despite the emergence of new therapies. However, treatment failure due to primary non-response or loss of response is common and often linked to low IFX trough levels (TLs) or anti-drug antibodies. Therapeutic drug monitoring (TDM) has thus become a valuable tool in optimizing IFX therapy. Frequent TDM, while beneficial, is not always practical due to cost and burden, making appropriate interval determination essential. Lim et al. conducted a longitudinal study of 228 IBD patients receiving IFX, performing TDM approximately every two months. They found that 85% of patients with TLs > 3 µg/mL at week 14 maintained therapeutic levels for over 13 months without pharmacokinetic (PK) relapse. Annual TDM may be sufficient for stable patients. Notably, drug antibodies were mostly detected after a drop in IFX levels, emphasizing the importance of preventing TL decline. The study had limitations, including limited analysis of immunomodulator use and generalizability due to regional treatment practices and patient population (predominantly Crohn’s disease). Moreover, the relationship between PK relapse and clinical outcomes remains unclear. Overall, combining IFX TDM with clinical, endoscopic, and biomarker monitoring may enhance patient outcomes. Genetic and serologic markers, such as HLA-DQA1*05 and PR3-ANCA, may help predict treatment response. Despite newer options, IFX remains central in IBD therapy, and individualized TDM strategies can support more effective and patient-centered care.
- 17 June 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (9) , 2944-2946
Open AccessAnnual Infliximab Monitoring After Treatment Optimization
Infliximab (IFX), a TNF-α inhibitor, remains a key treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, despite the emergence of new therapies. However, treatment failure due to primary non-response or loss of response is common and often linked to low IFX trough levels (TLs) or anti-drug antibodies. Therapeutic drug monitoring (TDM) has thus become a valuable tool in optimizing IFX therapy. Frequent TDM, while beneficial, is not always practical due to cost and burden, making appropriate interval determination essential. Lim et al. conducted a longitudinal study of 228 IBD patients receiving IFX, performing TDM approximately every two months. They found that 85% of patients with TLs > 3 µg/mL at week 14 maintained therapeutic levels for over 13 months without pharmacokinetic (PK) relapse. Annual TDM may be sufficient for stable patients. Notably, drug antibodies were mostly detected after a drop in IFX levels, emphasizing the importance of preventing TL decline. The study had limitations, including limited analysis of immunomodulator use and generalizability due to regional treatment practices and patient population (predominantly Crohn’s disease). Moreover, the relationship between PK relapse and clinical outcomes remains unclear. Overall, combining IFX TDM with clinical, endoscopic, and biomarker monitoring may enhance patient outcomes. Genetic and serologic markers, such as HLA-DQA1*05 and PR3-ANCA, may help predict treatment response. Despite newer options, IFX remains central in IBD therapy, and individualized TDM strategies can support more effective and patient-centered care.
- Open Access
- 6 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Optimal positioning of biomarkers according to ulcerative colitis activity
The diagnostic performance and clinical utility of fecal calprotectin (FC), fecal immunochemical occult blood test (FIT), leucine-rich alpha-2 glycoprotein (LRG), C-reactive protein (CRP), and prostaglandin E-major urinary metabolite (PGE-MUM) as established biomarkers for ulcerative colitis (UC) were evaluated. Significant correlations were observed between the clinical activity index, Mayo endoscopic subscore (MES), and each biomarker. Among MES groups, fecal biomarkers demonstrated significant differences, except between MES 2 and MES 3. CRP and LRG showed significant differences, except between MES 1 and MES 2. PGE-MUM exhibited significant differences across all MES groups. Areas under the curve (AUCs) for receiver operating characteristic (ROC) analysis in predicting MES 0 or 1 were as follows: FC, 0.891; FIT, 0.853; LRG, 0.723; CRP, 0.747; PGE-MUM, 0.795. For predicting MES 0 alone, AUCs were as follows: FC, 0.885; FIT, 0.845; LRG, 0.708; CRP, 0.691; PGE-MUM, 0.732. In distinguishing between each MES group, fecal biomarkers exhibited the highest AUC and accuracy in differentiating MES 0 from MES 1, whereas LRG, CRP, and PGE-MUM were most effective in differentiating MES 2 from MES 3. In summary, in UC, fecal biomarkers effectively detect mucosal healing, whereas LRG, CRP, and PGE-MUM are valuable for assessing mucosal healing and active inflammation.
- 6 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessOptimal positioning of biomarkers according to ulcerative colitis activity
The diagnostic performance and clinical utility of fecal calprotectin (FC), fecal immunochemical occult blood test (FIT), leucine-rich alpha-2 glycoprotein (LRG), C-reactive protein (CRP), and prostaglandin E-major urinary metabolite (PGE-MUM) as established biomarkers for ulcerative colitis (UC) were evaluated. Significant correlations were observed between the clinical activity index, Mayo endoscopic subscore (MES), and each biomarker. Among MES groups, fecal biomarkers demonstrated significant differences, except between MES 2 and MES 3. CRP and LRG showed significant differences, except between MES 1 and MES 2. PGE-MUM exhibited significant differences across all MES groups. Areas under the curve (AUCs) for receiver operating characteristic (ROC) analysis in predicting MES 0 or 1 were as follows: FC, 0.891; FIT, 0.853; LRG, 0.723; CRP, 0.747; PGE-MUM, 0.795. For predicting MES 0 alone, AUCs were as follows: FC, 0.885; FIT, 0.845; LRG, 0.708; CRP, 0.691; PGE-MUM, 0.732. In distinguishing between each MES group, fecal biomarkers exhibited the highest AUC and accuracy in differentiating MES 0 from MES 1, whereas LRG, CRP, and PGE-MUM were most effective in differentiating MES 2 from MES 3. In summary, in UC, fecal biomarkers effectively detect mucosal healing, whereas LRG, CRP, and PGE-MUM are valuable for assessing mucosal healing and active inflammation.
- 2 June 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (4) , 626-631
IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody
Interleukin-17 (IL-17) has been suggested to have a protective effect on the intestinal mucosa. The administration of an anti-IL-17 receptor monoclonal antibody has been associated with the onset of inflammatory bowel disease. We present a case of ulcerative colitis caused by secukinumab, an anti-IL-17 receptor A monoclonal antibody, that was treated with mirikizumab, a p19-directed antibody against IL-23. A man in his 20 s with psoriasis vulgaris was administered secukinumab at the dermatology department of our hospital. After the induction of secukinumab therapy, he gradually developed diarrhea, and after 4 months, bloody stools were observed. The patient was diagnosed with left-sided ulcerative colitis based on the findings of a colonoscopic examination. Secukinumab was discontinued and prednisolone was started; however, there was little improvement. His symptoms improved with the introduction of mirikizumab, and the condition is now clinically and endoscopically stable. In this case, an anti-IL-23 antibody was effective against ulcerative colitis induced by an Il-17A antibody agent. Although IL-23 exists upstream of the Th17 system, mirikizumab, an anti-IL-23 antibody preparation, has been shown to have the potential to alleviate UC.
- 2 June 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (4) , 626-631
IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody
Interleukin-17 (IL-17) has been suggested to have a protective effect on the intestinal mucosa. The administration of an anti-IL-17 receptor monoclonal antibody has been associated with the onset of inflammatory bowel disease. We present a case of ulcerative colitis caused by secukinumab, an anti-IL-17 receptor A monoclonal antibody, that was treated with mirikizumab, a p19-directed antibody against IL-23. A man in his 20 s with psoriasis vulgaris was administered secukinumab at the dermatology department of our hospital. After the induction of secukinumab therapy, he gradually developed diarrhea, and after 4 months, bloody stools were observed. The patient was diagnosed with left-sided ulcerative colitis based on the findings of a colonoscopic examination. Secukinumab was discontinued and prednisolone was started; however, there was little improvement. His symptoms improved with the introduction of mirikizumab, and the condition is now clinically and endoscopically stable. In this case, an anti-IL-23 antibody was effective against ulcerative colitis induced by an Il-17A antibody agent. Although IL-23 exists upstream of the Th17 system, mirikizumab, an anti-IL-23 antibody preparation, has been shown to have the potential to alleviate UC.